Yonsei Medical Center-Massachusetts General Hospital Collaborate on Developing Cell Therapy for Refractory Solid Tumors

Yonsei University Medical Center will collaborate with Massachusetts General Hospital in the United States to develop cell therapies for solid tumors.

Yoon Dong-seop, Director of the Medical Center (left), is signing an MOU with Mara Bloom, Senior Vice President (SVP) of Massachusetts General Hospital.
[Photo by Yonsei Medical Center]

On the 28th of last month (local time), Yonsei Medical Center announced on the 3rd that it signed a Memorandum of Understanding (MOU) with Massachusetts General Hospital at the Innovation Center in Cambridge, Boston, USA, to develop and research cell therapies for intractable solid tumors.

Both institutions agreed to jointly conduct the development and clinical research of cell therapies targeting stomach and esophageal cancers. The goal is to obtain approval for clinical trial plans (IND) from the U.S. Food and Drug Administration (FDA). They also plan to establish a network to share best practices in developing new treatments such as immunotherapy and cell therapy, and to promote exchanges among researchers in the fields of biotechnology and medicine.

Yoon Dong-seop, Director of the Medical Center, said, "This agreement recognizes Yonsei Medical Center's excellent clinical research capabilities," and added, "We plan to expand our network with various institutions to develop treatments for intractable solid tumors."

This content was produced with the assistance of AI translation services.